{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:07Z","timestamp":1787070847680,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pulmonary pleomorphic carcinoma, a relatively rare histopathological subtype of non-small cell lung cancer, is a malignant neoplasm with a poor prognosis. Despite the reports of a good response to immune-checkpoint inhibitor, only a few reports of pembrolizumab as the first-line treatment exist. We report the case of a 78-year-old male with right lung mass, mediastinal, right neck, and supraclavicular lymphadenopathies. He was diagnosed with pulmonary pleomorphic carcinoma, cT4N3M1c, Stage IVB. The tumor cells showed high programmed death-ligand 1 (PD-L1) expression but no microsatellite instability. After three cycles of pembrolizumab as the first-line therapy, chest computed tomography revealed marked reduction in tumor diameter. No remarkable adverse events occurred. The patient is alive with no complaints and no disease progression and has continued pembrolizumab for 8 months. Thus, first-line pembrolizumab therapy appears beneficial against pulmonary pleomorphic carcinoma, at least when PD-L1 expression is high. It is also effective in elderly patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_361_19","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:37Z","timestamp":1639526437000},"page":"1580-1582","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Pulmonary pleomorphic carcinoma in an elderly patient treated with pembrolizumab shows a marked response"],"prefix":"10.4103","volume":"17","author":[{"given":"Masahiro","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-49-20241021","first-page":"389","article-title":"Comparative analysis of tumor angiogenesis and clinical features of 55 cases of pleomorphic carcinoma and adenocarcinoma of the lung","volume":"35","author":"Tsubata","year":"2015","journal-title":"Anticancer Res"},{"key":"R2-49-20241021","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.lungcan.2017.07.020","article-title":"Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1","volume":"112","author":"Ikematsu","year":"2017","journal-title":"Lung Cancer"},{"key":"R3-49-20241021","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1159\/000479552","article-title":"The successful treatment of pulmonary pleomorphic carcinoma with pembrolizumab: A case report","volume":"10","author":"Matsumoto","year":"2017","journal-title":"Case Rep Oncol"},{"key":"R4-49-20241021","first-page":"398","article-title":"Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis","volume":"11","author":"Tozuka","year":"2018","journal-title":"Oxf Med Case Rep"},{"key":"R5-49-20241021","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1759-7714.12505","article-title":"Case series of pleomorphic carcinomas of the lung treated with nivolumab","volume":"8","author":"Kanazu","year":"2017","journal-title":"Thorac Cancer"},{"key":"R6-49-20241021","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2169\/internalmedicine.1462-18","article-title":"A High PD-L1 expression in pulmonary pleomorphic carcinoma correlates with parietal-pleural invasion and might predict a poor prognosis","volume":"58","author":"Naito","year":"2019","journal-title":"Intern Med"},{"key":"R7-49-20241021","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/jso.25041","article-title":"Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung","volume":"117","author":"Imanishi","year":"2018","journal-title":"J Surg Oncol"},{"key":"R8-49-20241021","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-49-20241021","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite Instability as a Biomarker for PD-1 Blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R10-49-20241021","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.18632\/oncotarget.23678","article-title":"The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages","volume":"9","author":"Wu","year":"2018","journal-title":"Oncotarget"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_361_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:35Z","timestamp":1787067455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_361_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_361_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}